A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations Meeting Abstract
| Authors: | Ball, B. J.; Stein, E.; Robbins, M.; Zhang, J.; Levine, R. L.; Synold, T.; Stein, A. S.; Marcucci, G.; Liu, Y.; Danilov, A. V. |
| Abstract Title: | A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 11761 |
| End Page: | 11762 |
| Language: | English |
| ACCESSION: | WOS:000893230304408 |
| DOI: | 10.1182/blood-2022-170820 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work